The criteria for discontinuation of oral hepatitis B antiviral drugs vary depending on whether the drug is E antigen positive or negative; for E antigen positive chronic hepatitis B, if the hepatitis B viral DNA is undetectable, transaminases are normalized, E antigen disappears and E antibodies are produced after one year of treatment, consolidate the treatment for at least three years and review it every six months during that period, and consider discontinuing the drug if it remains unchanged. For E antigen negative chronic hepatitis B, discontinuation can be considered when the hepatitis B surface antigen has disappeared and the hepatitis B virus DNA is undetectable. For both E antigen-positive and E antigen-negative chronic hepatitis B, a prolonged course of treatment can reduce relapses, and if cirrhosis is reached, long-term medication should be used and discontinuation is not recommended.